Plante M, Rubin S C, Wong G Y, Federici M G, Finstad C L, Gastl G A
Memorial Sloan-Kettering Cancer Center, New York, New York.
Cancer. 1994 Apr 1;73(7):1882-8. doi: 10.1002/1097-0142(19940401)73:7<1882::aid-cncr2820730718>3.0.co;2-r.
Interleukin-6 (IL-6) is a multifunctional cytokine that can be produced by human ovarian cancer cells. Elevated IL-6 levels have been found in the serum and ascites of patients with ovarian cancer, but its role in this disease has not been clearly established.
The authors studied the relationship between IL-6 levels in serum and ascites, various tumor parameters, and survival in 70 patients with newly diagnosed, untreated epithelial ovarian cancer. Ascites and serum specimens were obtained at the time of initial surgery, and IL-6 levels were determined using the B9 bioassay.
All patients underwent platinum-based chemotherapy after initial surgery. The median age of the group was 62 years (range, 28-87 years), and the median follow-up time was 13 months (range, 12-59 months). Significantly higher IL-6 levels were detected in patients' ascites (median, 49,612 pg/ml [range, < 1 to 680,330 pg/ml]) compared with serum (median, 10 pg/ml [range, < 1 to 1221 pg/ml]) (P < 0.0001). IL-6 levels in ascites correlated significantly with the volume of ascites (P < 0.0001) and nearly so with the size of tumor found at initial surgery (P = 0.05). Serum and ascites IL-6 levels did not correlate statistically with overall survival time, tumor stage, grade, histologic findings, residual tumor volume after debulking, and serum CA 125 levels. Although not statistically significant, patients who responded to chemotherapy tended to have lower ascites IL-6 levels (median, 21,102 pg/ml) compared with patients who did not respond to chemotherapy (median, 40,200 pg/ml).
IL-6 is present in very high amounts in the ascites of patients with epithelial ovarian cancer. IL-6 levels in ascites correlated significantly with ascites volume and initial tumor size. IL-6 levels in ascites and serum did not correlate statistically with other tumor parameters or with survival time.
白细胞介素-6（IL-6）是一种多功能细胞因子，可由人卵巢癌细胞产生。在卵巢癌患者的血清和腹水中已发现IL-6水平升高，但其在该疾病中的作用尚未明确。
作者研究了70例新诊断、未治疗的上皮性卵巢癌患者血清和腹水中IL-6水平、各种肿瘤参数与生存率之间的关系。在初次手术时获取腹水和血清标本，并使用B9生物测定法测定IL-6水平。
所有患者在初次手术后均接受了铂类化疗。该组患者的中位年龄为62岁（范围28 - 87岁），中位随访时间为13个月（范围12 - 59个月）。与血清（中位值10 pg/ml [范围<1至1221 pg/ml]）相比，患者腹水中检测到的IL-6水平显著更高（中位值49,612 pg/ml [范围<1至680,330 pg/ml]）（P < 0.0001）。腹水中的IL-6水平与腹水量显著相关（P < 0.0001），与初次手术时发现的肿瘤大小几乎也相关（P = 0.05）。血清和腹水IL-6水平与总生存时间、肿瘤分期、分级、组织学结果、减瘤术后残留肿瘤体积以及血清CA 125水平无统计学相关性。虽然无统计学意义，但与未对化疗产生反应的患者（中位值40,200 pg/ml）相比，对化疗有反应的患者腹水中IL-6水平往往较低（中位值21,102 pg/ml）。
上皮性卵巢癌患者的腹水中存在大量IL-6。腹水中的IL-6水平与腹水量和初始肿瘤大小显著相关。腹水和血清中的IL-6水平与其他肿瘤参数或生存时间无统计学相关性。
